Barclays’s Avalyn Pharma AVLN Stock Holding History

Barclays’s Portfolio AVLN Stock Details AVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$211K	Buy	7,419 +3,029	+69%	+$97.7K	﹤0.01%	3921
2026 Q2	$145K	Buy	+4,390	New	+$127K	﹤0.01%	3884

Other funds holding AVLN

Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Lewis Asset Management Lafayette, California $294M AUM 25.62% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Manchester Capital Management Manchester, Vermont $736M AUM 20.83% 1-Year Est. Return

Barclays's AVLN Position: Q3 2026 in Review

Barclays increased its Avalyn Pharma (AVLN) stake by 69% in Q3 2026, buying an estimated $97.7K and bringing the position to 7,419 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #3921.

Barclays first reported a position in AVLN in Q2 2026 and has held it in 2 quarters since. 23 funds tracked by Wall St. Rank hold AVLN as of Q3 2026.

Barclays held 7,419 shares of Avalyn Pharma worth $211K as of Q3 2026.
Barclays bought 3,029 Avalyn Pharma shares in Q3 2026, an estimated $97.7K.
Avalyn Pharma made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3921 holding.
Barclays first reported a position in Avalyn Pharma in Q2 2026 and has held it in 2 quarters since.
23 funds tracked by Wall St. Rank held Avalyn Pharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.